The groundbreaking success of the copyright undeniably transformed the drug landscape, but investing in companies heavily reliant on unbranded versions presents a uncertain picture. While early profits were impressive, the expiration of patents and the emergence of discounted alternatives have diminished market share. Therefore, a thorough analysis